<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RENAGEL- sevelamer hydrochloride tablet </strong><br>Atlantic Biologicals Corps<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Renagel safely and
    effectively. See full prescribing information for Renagel. Renagel (sevelamer hydrochloride) Tablet for Oral use Initial U.S. Approval: 2000
        <br><br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul><li>Renagel is a phosphate binder indicated for the
                    control of serum phosphorus in patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> on dialysis.
                      ( )
                                        <span class="Sup">®</span><a href="#d722c358-c84e-43fd-a768-7496db4f7df9">1</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Starting dose is one or two 800 mg or two to four 400 mg tablets three
                    times per day with meals. ( )
                                        <a href="#e7fe98cd-11fc-47c6-9893-9b7d3a3b7ceb">2</a>
</li>
<li>Adjust by one tablet per meal in two week intervals as needed to obtain
                    serum phosphorus target 3.5 to 5.5 mg/dL. ( )
                                        <a href="#e7fe98cd-11fc-47c6-9893-9b7d3a3b7ceb">2</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Tablets: 800 mg and 400 mg ( )
                                        <a href="#ad75e659-61f8-4158-a743-113f58734b9b">3</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>In patients with <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>. ( )
                                        <a href="#d1e87d44-1147-4fdc-a7f4-b20d02299b86">4</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li>Serious cases of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. ( )
                                        <a href="#b6a267e2-62e5-4922-a258-f27bb2ce7875">5.1</a>
</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul>
<li>The most common reasons for discontinuing treatment were gastrointestinal
                    adverse reactions. ( )
                                        <a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>
</li>
<li>In a parallel design study, of 12 weeks duration, treatment
                    emergent adverse reactions to Renagel Tablets in peritoneal
                    dialysis patients included <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (12%), <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> (8%),
                    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
                    (4%), <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (4%), <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span> (3%),
                    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (3%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (3%), and
                    <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (3%). ( )
                                        <a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>
</li>
<li>Similar reactions at similar rates occurred in hemodialysis and peritoneal
                    dialysis patients. ( )
                                        <a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>
</li>
<li>Cases of <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> and, less commonly, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and
                    <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span> have been reported. ( )
                                        <a href="#df163be9-d042-4ccd-9d79-e8823244bc15">6.2</a>
</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact
                      Genzyme Corporation at 1-800-847-0069 and  or FDA at 1-800-FDA-1088
                      or www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Decreases the bioavailability of ciprofloxacin by approximately
                    50%. ( )
                                        <a href="#a8f01da4-6d28-43c3-ae2d-213fb51d46f4">7.1</a>
</li>
<li>In normal volunteer studies, sevelamer hydrochloride did not alter the
                    pharmacokinetics of a single dose of digoxin, warfarin, enalapril, metoprolol,
                    and iron. ( )
                                        <a href="#d5c43250-b562-48a8-9f43-1aca12917563">7</a>
</li>
<li>When administering an oral medication where a reduction in the
                    bioavailability of that medication would have a clinically significant effect on
                    its safety or efficacy, the drug should be administered at least one
                    hour before or three hours after Renagel, or the physician should consider
                    monitoring blood levels of the drug. ( )
                                        <a href="#e7e1f620-31bb-44e8-b87b-095245b88187">7.7</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 5/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Gastrointestinal Adverse Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Monitor Serum Chemistries</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and Folic Acid
                Levels</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Ciprofloxacin</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Digoxin</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Warfarin</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Enalapril</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Metoprolol</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Iron</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Other Concomitant Drug Therapy</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Active-Control, Cross-Over Study in Hemodialysis Patients</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Active-Control, Parallel Study in Hemodialysis Patients</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Active-Control, Parallel Study in Peritoneal Dialysis Patients</a></h2>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-14.1" class="toc">17.1 Dosing Recommendations</a></h2>
<h2><a href="#section-14.2" class="toc">17.2 Adverse Reactions</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="d722c358-c84e-43fd-a768-7496db4f7df9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">RENAGEL  (sevelamer
              hydrochloride) is indicated for the control of serum phosphorus in patients with
              <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) on dialysis. The safety and efficacy of Renagel in CKD
              patients who are not on dialysis have not been studied.
                            <span class="Sup">®</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>  Renagel is a
                Registered Trademark of Genzyme Corporation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="e7fe98cd-11fc-47c6-9893-9b7d3a3b7ceb"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">. The recommended starting dose of Renagel is 800 to 1600 mg, which can be
              administered as one or two 800 mg Renagel Tablets or two
              to four 400 mg Renagel Tablets, with meals based on
              serum phosphorus level. provides recommended starting doses of Renagel for patients not taking
              a phosphate binder.
                            <span class="Italics"><span class="Emphasis">Patients Not Taking a Phosphate Binder</span></span><span class="Sup">®</span><span class="Sup">®</span><a href="#dc96a9a6-295a-4c09-8877-2c1f8d30952e">Table
                1</a></p>
<a name="dc96a9a6-295a-4c09-8877-2c1f8d30952e"></a><table>
<caption><span>Table 1. Starting Dose for Dialysis Patients Not Taking a Phosphate
                Binder</span></caption>
<colgroup>
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Serum Phosphorus</span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">®</span></span></span><span class="Bold"><span class="Emphasis">800 mg</span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">®</span></span></span><span class="Bold"><span class="Emphasis">400 mg</span></span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&gt; 5.5 and &lt; 7.5 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 tablet three times daily with meals</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 tablets three times daily with meals</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">≥ 7.5 and &lt; 9.0 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 tablets three times daily with meals</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 tablets three times daily with meals</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">≥ 9.0 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 tablets three times daily with meals</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4 tablets three times daily with meals</p></td>
</tr>
</tbody>
</table>
<p>. In a study in 84 CKD patients on hemodialysis, a similar reduction in
              serum phosphorus was seen with equivalent doses (approximately mg for mg) of Renagel
              and calcium acetate. gives recommended starting doses of Renagel based on a
              patient’s current calcium acetate dose.
                            <span class="Italics"><span class="Emphasis">Patients Switching From Calcium Acetate</span></span><a href="#d93597ec-8962-496d-b5a9-4561f84e9427">Table
                2</a></p>
<a name="d93597ec-8962-496d-b5a9-4561f84e9427"></a><table>
<caption><span>Table 2. Starting Dose for Dialysis Patients Switching From Calcium Acetate
                to Renagel</span></caption>
<colgroup>
<col align="center">
<col align="center">
<col align="center">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold"><span class="Emphasis">Calcium Acetate 667 mg (Tablets per meal)
                                                <br></span></span></th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Renagel 800
                                                <span class="Sup">®</span></span></span><span class="Bold"><span class="Emphasis">mg (Tablets per meal)
                                                <br></span></span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center">
<span class="Bold"><span class="Emphasis">Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">®</span></span></span><span class="Bold"><span class="Emphasis">400</span></span><span class="Bold"><span class="Emphasis">mg</span></span><span class="Bold"><span class="Emphasis">(Tablets per meal)
                                                <br></span></span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1 tablet</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1 tablet</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2 tablets</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2 tablets</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2 tablets</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3 tablets</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3 tablets</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3 tablets</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">5 tablets</p></td>
</tr>
</tbody>
</table>
<p>. Dosage should be adjusted based on the serum phosphorus concentration with
              a goal of lowering serum phosphorus to 5.5 mg/dL or less. The dose may be increased or
              decreased by one tablet per meal at two week intervals as necessary. gives a dose
              titration guideline. The average dose in a Phase 3 trial designed to lower serum
              phosphorus to 5.0 mg/dL or less was approximately three Renagel 800 mg tablets per
              meal. The maximum average daily Renagel dose studied was 13 grams.
                            <span class="Italics"><span class="Emphasis">Dose Titration for All Patients Taking
                  Renagel</span></span><a href="#e6083c2f-981c-4742-aef3-40abe7e9edd4">Table 3</a></p>
<a name="e6083c2f-981c-4742-aef3-40abe7e9edd4"></a><table>
<caption><span>Table 3. Dose Titration Guideline</span></caption>
<colgroup>
<col align="left">
<col align="left">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis">Serum Phosphorus</span></span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis">Renagel Dose
                                                <span class="Sup">®</span></span></span><br>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">&gt;5.5 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Increase 1 tablet per meal at 2 week intervals</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">3.5 - 5.5 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Maintain current dose</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">&lt;3.5 mg/dL</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Decrease 1 tablet per meal</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ad75e659-61f8-4158-a743-113f58734b9b"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">800 mg and 400 mg Tablets.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="d1e87d44-1147-4fdc-a7f4-b20d02299b86"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Renagel is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="cde8d2df-be16-4209-8632-682614db1230"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="b6a267e2-62e5-4922-a258-f27bb2ce7875"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Gastrointestinal Adverse Events</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and esophageal tablet retention have been reported in association with
                use of the tablet formulation of sevelamer, some requiring hospitalization and intervention. Consider 
                using sevelamer suspension in patients with a history of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>. Cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> 
                and perforation have also been reported with sevelamer use. Patients with <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>,
                severe gastrointestinal (GI) motility disorders including severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, or major GI tract surgery 
                were not included in the Renagel clinical studies.
                                    <br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e5b5645a-da07-4eec-a93b-91d333c316ff"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Monitor Serum Chemistries</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> and chloride levels should be monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b3133303-2178-477f-8082-a955dc9c5e21"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Monitor for Reduced Vitamins D, E, K (clotting factors) and Folic Acid
                Levels</h2>
<p class="First">In preclinical studies in rats and dogs, sevelamer hydrochloride reduced
                  vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of
                  6-10 times the recommended human dose. In short-term clinical trials,
                  there was no evidence of reduction in serum levels of vitamins.  However,
                  in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55
                  ng/mL) fell from 39 ± 22 ng/mL to 34 ± 22 ng/mL (p&lt;0.01)
                  with sevelamer hydrochloride treatment. Most (approximately 75%)
                  patients in sevelamer hydrochloride clinical trials received
                  vitamin supplements, which is typical of patients on dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="f7c5cfb3-6f6d-464d-8436-d526a66e45be"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ac6c2ee2-f040-4dd1-969f-65b720d1e830"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions,
                  adverse reaction rates observed in the clinical trials of a drug can not be
                  directly compared to rates in the clinical trials of another drug and may not
                  reflect the rates observed in practice.</p>
<p>In a parallel design study of sevelamer hydrochloride with treatment
                  duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride
                  (n=99) were similar to those reported for the active-control group (n=101).
                  Overall adverse reactions among those treated with sevelamer hydrochloride
                  occurring in &gt; 5% of patients included: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (22%),
                  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (20%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (19%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (16%), abdominal
                  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (9%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (8%) and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (8%). A total
                  of 27 patients treated with sevelamer and 10 patients treated with comparator
                  withdrew from the study due to adverse reactions.</p>
<p>Based on studies of 8-52 weeks, the most common reason for withdrawal
                  from Renagel was gastrointestinal adverse reactions (3-16%).</p>
<p>In one hundred and forty-three peritoneal dialysis patients studied
                  for 12 weeks most adverse reactions were similar to adverse reactions
                  observed in hemodialysis patients. The most frequently occurring treatment
                  emergent serious adverse reaction was <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> (8 reactions in 8 patients
                  [8%] in the sevelamer group and 2 reactions in 2 patients [4%] on
                  active-control). Thirteen patients (14%) in the sevelamer group and 9
                  patients (20%) in the active-control group discontinued, mostly for
                  gastrointestinal adverse reactions. Patients on peritoneal dialysis should be
                  closely monitored to ensure the reliable use of appropriate aseptic technique with
                  the prompt recognition and management of any signs and symptoms associated with
                  <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="df163be9-d042-4ccd-9d79-e8823244bc15"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during
                  post-approval use of sevelamer hydrochloride (Renagel ):
                  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> and uncommon cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>,
                  <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>. Appropriate medical management
                  should be given to patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or have worsening of existing
                  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> to avoid severe complications.
                                    <span class="Sup">®</span></p>
<p>Because these reactions are reported voluntarily from a population of
                  uncertain size, it is not always possible to estimate their frequency or to
                  establish a causal relationship to drug exposure.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="d5c43250-b562-48a8-9f43-1aca12917563"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Renagel has been studied in human drug-drug interaction studies with
              ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="a8f01da4-6d28-43c3-ae2d-213fb51d46f4"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Ciprofloxacin</h2>
<p class="First">In a study of 15 healthy subjects, a co-administered single dose of 7
                  Renagel capsules (approximately 2.8 g) decreased the bioavailability of
                  ciprofloxacin by approximately 50%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a4993b6d-7653-4dc0-944f-d201036b8467"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Digoxin</h2>
<p class="First">In 19 healthy subjects receiving 6 Renagel capsules three times a day
                  with meals for 2 days, Renagel did not alter the pharmacokinetics of a single dose
                  of digoxin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e39a029f-56f1-4abd-98b8-cef122791d61"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Warfarin</h2>
<p class="First">In 14 healthy subjects receiving 6 Renagel capsules three times a day
                  with meals for 2 days, Renagel did not alter the pharmacokinetics of a single dose
                  of warfarin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d83937de-94d0-4471-9bc9-a0de53762ec1"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Enalapril</h2>
<p class="First">In 28 healthy subjects a single dose of 6 Renagel capsules did not alter
                  the pharmacokinetics of a single dose of enalapril.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a6dca540-acce-4667-8fdb-10bfd6279c3a"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Metoprolol</h2>
<p class="First">In 31 healthy subjects a single dose of 6 Renagel capsules did not alter
                  the pharmacokinetics of a single dose of metoprolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ce9a277e-b267-4710-987b-5df520ef9944"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Iron</h2>
<p class="First">In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter
                  the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate
                  tablet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e7e1f620-31bb-44e8-b87b-095245b88187"></a><a name="section-7.7"></a><p></p>
<h2>7.7 Other Concomitant Drug Therapy</h2>
<p class="First">There are no empirical data on avoiding drug interactions between
                    Renagel and most concomitant drugs. During postmarketing
                  experience, very rare cases of increased thyroid stimulating hormone (TSH) levels
                  have been reported in patients co-administered sevelamer hydrochloride and
                  levothyroxine. Closer monitoring of TSH levels is therefore recommended in
                  patients receiving both medications.
                                    <span class="Sup">®</span></p>
<p>When administering an oral medication where a reduction in the
                  bioavailability of that medication would have a clinically significant effect on
                  its safety or efficacy, the drug should be administered at least one hour before
                  or three hours after Renagel, or the physician should consider monitoring blood
                  levels of the drug. Patients taking anti-arrhythmic medications for the control of
                  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medications for the control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders were
                  excluded from the clinical trials. Special precautions should be taken when
                  prescribing Renagel to patients also taking these medications.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="a24f0dfd-6c5f-4d6a-acd8-b67133cdedfa"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="e1281628-37b8-45d1-8dec-131836795328"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C: The effect of Renagel on the absorption of
                  vitamins and other nutrients has not been studied in pregnant women. Requirements
                  for vitamins and other nutrients are increased in pregnancy. In pregnant rats
                  given doses of Renagel during organogenesis, reduced or irregular ossification of
                  fetal bones, probably due to a reduced absorption of fat-soluble vitamin D,
                  occurred. In pregnant rabbits given oral doses of Renagel by gavage during
                  organogenesis, an increase of early resorptions occurred.
                                    <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[See</span></span><a href="#cc23b3c3-9818-4840-a9e7-98ee77d93dc0">NONCLINICAL TOXICOLOGY
                        (13.1)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="caa42930-468d-4da9-8a96-d3f38c1edbcd"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">No Renagel treatment-related effects on labor and delivery were seen in
                  animal studies. The effects of Renagel on labor and delivery in
                  humans are not known.
                                    <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[See</span></span><a href="#cc23b3c3-9818-4840-a9e7-98ee77d93dc0">NONCLINICAL TOXICOLOGY
                        (13.1)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="c2bad6b6-975f-4597-bd2c-6fbaa53e2a60"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Renagel has not been established in pediatric
                  patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="a60172fb-e781-4ab3-8c5c-70b9bb61dfed"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Renagel did not include sufficient numbers of
                  subjects aged 65 and over to determine whether they respond differently from
                  younger subjects. Other reported clinical experience has not identified
                  differences in responses between the elderly and younger patients. In general,
                  dose selection for an elderly patient should be cautious, usually starting at the
                  low end of the dosing range.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="b1e5f2ae-8d19-4f4f-8dc2-ab5e3938d65a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Renagel has been given to normal healthy volunteers in doses of up to 14
              grams per day for eight days with no adverse effects. Renagel has been given in
              average doses up to 13 grams per day to hemodialysis patients. There are no reports of
              overdosage with Renagel in patients. Since Renagel is not absorbed, the risk of
              systemic toxicity is low.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="f15b9dff-e9ba-4317-afaf-a0620ae1dc68"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">The active ingredient in Renagel Tablets is sevelamer hydrochloride, a
              polymeric amine that binds phosphate and is meant for oral administration. Sevelamer
              hydrochloride is poly(allylamine hydrochloride) crosslinked with epichlorohydrin in
              which forty percent of the amines are protonated. It is known chemically as
                poly(allylamine- -N,N’-diallyl-1,3-diamino-2-hydroxypropane) hydrochloride.
              Sevelamer hydrochloride is hydrophilic, but insoluble in water. The structure is
              represented in .
                            <span class="Underline"><span class="Emphasis">co</span></span><a href="#MM280">Figure 1</a></p>
<p><span class="Bold"><span class="Emphasis">Figure 1. Chemical Structure of Sevelamer
                  Hydrochloride</span></span></p>
<p><img alt="Figure 1. Chemical Structure of Sevelamer Hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee835dc1-36b7-4447-a5c6-5ed9e06a839d&amp;name=renagel-figure-1.jpg"></p>
<p>      a, b = number of
              primary amine
              groups                 a
              + b = 9</p>
<p>      c = number of
              crosslinking
              groups                         c
              = 1</p>
<p>      n = fraction of
              protonated
              amines                          n
              = 0.4</p>
<p>      m = large number
              to indicate extended polymer network</p>
<p>The primary amine groups shown in the structure are derived directly from
              poly(allylamine hydrochloride). The crosslinking groups consist of two secondary amine
              groups derived from poly(allylamine hydrochloride) and one molecule of
              epichlorohydrin.</p>
<p>Each film-coated tablet of Renagel contains either 800 mg or 400 mg of
              sevelamer hydrochloride on an anhydrous basis. The inactive ingredients are
              hypromellose, diacetylated monoglyceride, colloidal silicon dioxide, and stearic acid.
              The tablet imprint contains iron oxide black ink.
                            <span class="Bold"><span class="Emphasis">Renagel Tablets:
                                    <span class="Sup">®</span></span></span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="d44a5bc3-4dea-4e18-84a2-2ca5c4392fc5"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) on dialysis retain phosphorus and
              can develop <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. High serum phosphorus can precipitate serum calcium
              resulting in ectopic calcification. When the product of serum calcium and phosphorus
              concentrations (Ca x P) exceeds 55 mg /dL , there is an
              increased risk that ectopic calcification will occur. <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">Hyperphosphatemia</span> plays a role
              in the development of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.
                            <span class="Sup">2</span><span class="Sup">2</span></p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> includes reduction in dietary intake of
              phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and
              removal of phosphate with dialysis. Renagel taken with meals has been shown to
              decrease serum phosphorus concentrations in patients with CKD who are on
              dialysis.</p>
<div class="Section" data-sectionCode="43679-0">
<a name="f28552f8-fe8c-457d-b01a-0a35bb4b1ea1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Renagel contains sevelamer hydrochloride, a non-absorbed binding
                  crosslinked polymer. It contains multiple amines separated by one carbon from the
                  polymer backbone. These amines exist in a protonated form in the intestine and
                  interact with phosphate molecules through ionic and hydrogen bonding. By binding
                  phosphate in the dietary tract and decreasing absorption, sevelamer hydrochloride
                  lowers the phosphate concentration in the serum.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="c6db5a84-c721-4d72-a20f-2d657faa09c3"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In addition to effects on serum phosphate levels, sevelamer
                  hydrochloride has been shown to bind bile acids and in experimental animal models. Bile acid binding by ion exchange resins
                  is a well-established method of lowering blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Because sevelamer
                  binds bile acids, it may interfere with normal fat absorption and thus may reduce
                  absorption of fat-soluble vitamins such as A, D and K. In clinical trials of
                  sevelamer hydrochloride, both the mean total and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> declined by
                  15-31%. This effect is observed after 2 weeks. Triglycerides, HDL
                  <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and albumin did not change.
                                    <span class="Italics"><span class="Emphasis">in vitro</span></span><span class="Italics"><span class="Emphasis">in vivo</span></span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="da5d77f6-2e44-4f3a-81fa-825a0a5b444b"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study using C-sevelamer hydrochloride in 16
                  healthy male and female volunteers showed that sevelamer hydrochloride is not
                  systemically absorbed. No absorption studies have been performed in patients with
                  <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.
                                    <span class="Sup">14</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="e2c7c99c-74a5-41ce-b06b-096d8fdba411"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="cc23b3c3-9818-4840-a9e7-98ee77d93dc0"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Standard lifetime carcinogenicity bioassays were conducted in mice and
                  rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 g/kg/day.
                  There was an increased incidence of urinary bladder transitional cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> in
                  male rats of the high dose group (human equivalent dose twice the maximum clinical
                  trial dose of 13 g). Mice received dietary administration of sevelamer
                  hydrochloride at doses of up to 9 g/kg/day (human equivalent dose 3 times the
                  maximum clinical trial dose). There was no increased incidence of tumors observed
                  in mice.</p>
<p>In an mammalian cytogenetic test with metabolic activation, sevelamer
                  hydrochloride caused a statistically significant increase in the number of
                  structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in
                  the Ames bacterial mutation assay.
                                    <span class="Italics"><span class="Emphasis">in vitro</span></span></p>
<p>Sevelamer hydrochloride did not impair the fertility of male or female
                  rats in a dietary administration study in which the females were treated from 14
                  days prior to mating through gestation and the males were treated for 28 days
                  prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent
                  dose 3 times the maximum clinical trial dose of 13 g).</p>
<p>In pregnant rats given dietary doses of 0.5, 1.5 or 4.5 g/kg/day of
                  sevelamer hydrochloride during organogenesis, reduced or irregular ossification of
                  fetal bones, probably due to a reduced absorption of fat-soluble vitamin D,
                  occurred in mid- and high-dose groups (human equivalent doses less than the
                  maximum clinical trial dose of 13 g). In pregnant rabbits given oral doses of 100,
                  500 or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis,
                  an increase of early resorptions occurred in the high-dose group (human equivalent
                  dose twice the maximum clinical trial dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="c64a1d9e-37f3-46f8-ba15-703b797a658e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The ability of Renagel to lower serum phosphorus in CKD patients on dialysis
              was demonstrated in six clinical trials: one double-blind placebo controlled 2-week
              study (Renagel N=24); two open-label uncontrolled 8-week studies (Renagel N=220) and
              three active-controlled open-label studies with treatment durations of 8 to 52 weeks
              (Renagel N=256). Three of the active-controlled studies are described here. One is a
              crossover study with two 8-week periods comparing Renagel to an active-control. The
              second is a 52-week parallel study comparing Renagel with active-control. The third is
              a 12-week parallel study comparing Renagel and active-control in peritoneal dialysis
              patients.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="cc408018-eeaa-4aeb-8bf5-bf880595d736"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Active-Control, Cross-Over Study in Hemodialysis Patients</h2>
<p class="First">Eighty-four CKD patients on hemodialysis who were hyperphosphatemic
                  (serum phosphorus &gt; 6.0 mg/dL) following a two-week phosphate binder
                  washout period received Renagel and active-control for eight weeks each in random
                  order. Treatment periods were separated by a two-week phosphate binder washout
                  period. Patients started on treatment three times per day with meals. Over each
                  eight-week treatment period, at three separate time points the dose of Renagel
                  could be titrated up 1 capsule or tablet per meal (3 per day) to control serum
                  phosphorus, the dose of active-control could also be altered to attain phosphate
                  control. Both treatments significantly decreased mean serum phosphorus by about 2
                  mg/dL ( ).
                                    <a href="#fcb9773c-a79b-4976-85b7-e3545f471acc">Table 4</a></p>
<a name="fcb9773c-a79b-4976-85b7-e3545f471acc"></a><table>
<caption><span>Table 4. Mean Serum Phosphorus (mg/dL) at Baseline and Endpoint</span></caption>
<colgroup><col align="left"></colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left"><br></th>
<th class="Botrule Lrule Rrule Toprule" align="center">Renagel (N=81)
                                                <span class="Sup">®</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center"> Active-Control (N=83)
                                                <br>
</th>
</tr></thead>
<tfoot><tr><td colspan="1" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>p&lt;0.0001, within treatment group
                          comparison</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Baseline at End of Washout</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">Endpoint</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6.4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5.9</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Change from Baseline at Endpoint</p>
<p>(95% Confidence Interval)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-2.0
                                                    <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p>
<p>(-2.5, -1.5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">-2.1
                                                    <a href="#footnote-2" class="Sup">*</a></p>
<p>(-2.6, -1.7)</p>
</td>
</tr>
</tbody>
</table>
<p>The distribution of responses is shown in . The distributions are similar for sevelamer
                  hydrochloride and active control. The median response is a reduction of about 2
                  mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL.
                                    <a href="#MM350">Figure 2</a></p>
<p><span class="Bold"><span class="Emphasis">Figure 2. Percentage of patients (Y-axis)
                      attaining a phosphorus reduction from baseline (mg/dL) at least as great as
                      the value of the X-axis.</span></span></p>
<p><img alt="Figure 2. Percentage of patients (Y-axis) attaining a phosphorus reduction
                    from baseline (mg/dL) at least as great as the value of the X-axis." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee835dc1-36b7-4447-a5c6-5ed9e06a839d&amp;name=renagel-figure-2.jpg"></p>
<p>Average daily Renagel dose at the end of treatment was 4.9 g (range of
                  0.0 to 12.6 g).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="dc2627e4-aa8c-42af-8c83-1c18b02729ab"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Active-Control, Parallel Study in Hemodialysis Patients</h2>
<p class="First">Two hundred CKD patients on hemodialysis who were hyperphosphatemic
                  (serum phosphorus &gt;5.5 mg/dL) following a two-week phosphate binder washout
                  period were randomized to receive Renagel 800 mg tablets (N=99) or an
                  active-control (N=101). The two treatments produced similar decreases in serum
                  phosphorus. At week 52, using last-observation-carried-forward, Renagel and
                  active-control both significantly decreased mean serum
                    phosphorus ( ).
                                    <a href="#bff8bfec-c053-4c90-be5c-aa4686cdf649">Table 5</a></p>
<a name="bff8bfec-c053-4c90-be5c-aa4686cdf649"></a><table>
<caption><span>Table 5. Mean Serum Phosphorus (mg/dL) and Ion Product at Baseline and
                    Change from Baseline to End of Treatment</span></caption>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<thead class="Botrule Lrule Rrule Toprule"><tr class="Last">
<th class="Botrule Lrule Rrule Toprule" align="left"><br></th>
<th class="Botrule Lrule Rrule Toprule" align="center">Renagel (N=94)
                                                <span class="Sup">®</span><br>
</th>
<th class="Botrule Lrule Rrule Toprule" align="center">Active-Control (N=98)
                                                <br>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Phosphorus</p>
<p>Baseline</p>
<p>Change from Baseline at Endpoint</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<br><p class="First">7.5</p>
<p>-2.1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<br><p class="First">7.3</p>
<p>-1.8</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Ca x Phosphorus Ion Product</p>
<p>Baseline</p>
<p>Change from Baseline at Endpoint</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<br><p class="First"> 70.5</p>
<p>-19.4</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<br><p class="First"> 68.4</p>
<p>-14.2</p>
</td>
</tr>
</tbody>
</table>
<p>Sixty-one percent of Renagel patients and 73% of the control
                  patients completed the full 52 weeks of treatment.</p>
<p>, a plot of the phosphorus change from
                  baseline for the completers, illustrates the durability of response for patients
                  who are able to remain on treatment.
                                    <a href="#MM360">Figure 3</a></p>
<p><span class="Bold"><span class="Emphasis">Figure 3. Mean Phosphorus Change from Baseline for
                      Patients who Completed 52 Weeks of Treatment</span></span></p>
<p><img alt="Figure 3. Mean Phosphorus Change from Baseline for Patients who Completed 52
                    Weeks of Treatment" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee835dc1-36b7-4447-a5c6-5ed9e06a839d&amp;name=renagel-figure-3.jpg"></p>
<p>Average daily Renagel dose at the end of treatment was 6.5 g (range of
                  0.8 to 13 g).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e4bf7cda-4ed0-49b1-a872-251efe2af8dc"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Active-Control, Parallel Study in Peritoneal Dialysis Patients</h2>
<p class="First">One hundred and forty-three patients on peritoneal dialysis who were
                  hyperphosphatemic (serum phosphorus &gt; 5.5 mg/dL) following a two-week
                  phosphate binder washout period were randomized to receive
                    Renagel (N=97) or active-control (N=46) open label for 12
                  weeks. Average daily Renagel dose at the end of treatment was 5.9 g (range 0.8 to
                  14.3 g). There were statistically significant changes in serum phosphorus
                  (p&lt;0.001) for Renagel (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to
                  the active-control.
                                    <span class="Sup">®</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="eb5ced02-2bb2-4482-8c6c-a4f240f2fa9a"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e06f2493-be90-43d6-b1be-57466b549a61"></a><a name="section-14.1"></a><p></p>
<h2>17.1 Dosing Recommendations</h2>
<p class="First">The prescriber should inform patients to take Renagel with meals and
                  adhere to their prescribed diets. Instructions should be given on concomitant
                  medications that should be dosed apart from Renagel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ccda8586-fbcd-4b43-9502-1bddc3f81e64"></a><a name="section-14.2"></a><p></p>
<h2>17.2 Adverse Reactions</h2>
<p class="First">Renagel may cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> that if left untreated, may lead to severe
                  complications. Patients should be cautioned to report new onset or worsening of
                  existing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> promptly to their physician.</p>
<p>Distributed by:</p>
<p>Genzyme Corporation</p>
<p>500 Kendall Street</p>
<p>Cambridge, MA 02142 USA</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="eddb27fd-7bf4-4fd4-8a45-59ae220f3ddd"></a><a name="section-15"></a><p></p>
<h1>RENAGEL TABLET</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ee835dc1-36b7-4447-a5c6-5ed9e06a839d&amp;name=rspl17856-0021.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RENAGEL 		
					</strong><br><span class="contentTableReg">renagel tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17856-0021(NDC:58468-0021)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SEVELAMER HYDROCHLORIDE</strong> (SEVELAMER) </td>
<td class="formItem">SEVELAMER HYDROCHLORIDE</td>
<td class="formItem">800 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">3.2 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">3.2 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">64.6 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem">16.7 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">16.7 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RENAGEL;800</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17856-0021-2</td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021179</td>
<td class="formItem">06/06/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Atlantic Biologicals Corps
							(047437707)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Atlantic Biologicals Corps (047437707)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Atlantic Biologicals Corps</td>
<td class="formItem"></td>
<td class="formItem">047437707</td>
<td class="formItem">RELABEL(17856-0021), REPACK(17856-0021)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>42719fda-d898-4749-b561-f85a5e54cd06</div>
<div>Set id: ee835dc1-36b7-4447-a5c6-5ed9e06a839d</div>
<div>Version: 3</div>
<div>Effective Time: 20121206</div>
</div>
</div> <div class="DistributorName">Atlantic Biologicals Corps</div></p>
</body></html>
